In 2013, ADCs achieved another breakthrough with the approval of Trastuzumab emtansine (TDM‐1) by the US FDA for human epidermal growth factor receptor‐2 (HER2)‐positive breast cancer.7 The gene discussed is ERBB2; the disease is breast cancer.